Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $111.9 million.

  • Mirum Pharmaceuticals' Accumulated Expenses rose 41.54% to $148.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.2 million, marking a year-over-year increase of 41.54%. This contributed to the annual value of $111.9 million for FY2024, which is 42.51% up from last year.
  • As of FY2024, Mirum Pharmaceuticals' Accumulated Expenses stood at $111.9 million, which was up 42.51% from $78.5 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Accumulated Expenses peaked at $111.9 million during FY2024, and registered a low of $13.4 million during FY2020.
  • In the last 3 years, Mirum Pharmaceuticals' Accumulated Expenses had a median value of $78.5 million in 2023 and averaged $81.5 million.
  • Data for Mirum Pharmaceuticals' Accumulated Expenses shows a peak YoY surged of 129.09% (in 2021) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' Accumulated Expenses (Yearly) stood at $13.4 million in 2020, then soared by 129.09% to $30.7 million in 2021, then skyrocketed by 75.82% to $54.0 million in 2022, then skyrocketed by 45.40% to $78.5 million in 2023, then soared by 42.51% to $111.9 million in 2024.